



RPG LIFE SCIENCES LIMITED

Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India
Tel: +91-22-25292152-55 ♦ Fax: +91-22-25297423

July 28, 2015

To

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051	BSE Limited Floor 25, P.J. Towers Dalal Street Mumbai 400 001
---	--


Dear Sirs,

Sub: Unaudited financial results for the quarter ended June 30, 2015
(Scrip Code: RPGLIFE / 532983)


We submit herewith the unaudited financial results along with limited review report of the statutory auditors for the quarter ended June 30, 2015. These results have been reviewed by the Audit Committee and have been approved and taken on record by Board of Directors at its respective meetings held on July 28, 2015.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shirambekar

Head - Legal & Company Secretary




Encl: As above



RPG LIFE SCIENCES LIMITED

PART I				(Rs. in lakhs)
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE, 2015				
Particulars	3 months ended 30.6.2015 Unaudited	3 months ended 31.3.2015 Unaudited	3 months ended 30.6.2014 Unaudited	Year ended 31.03.2015 Audited
1. Income from Operations				
(a) Net Sales/Income from Operations (Net of Excise Duty)	6,650	6,119	5,879	23,308
(b) Other Operating Income	94	557	79	919
Total Income from Operations (Net)	6,744	6,676	5,958	24,227
2. Expenses				
(a) Cost of Materials Consumed	1,311	1,222	1,526	5,920
(b) Purchases of Stock-in-Trade	777	505	516	2,378
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	290	389	233	171
(d) Employee Benefits Expense	1,777	1,730	1,561	6,866
(e) Depreciation and Amortisation Expense	255	304	226	1,136
Provision for Doubtful Debts and Advances (Net)				
(f)	16	63	9	(323)
(g) Other Expenses	2,038	1,921	1,765	7,798
Total Expenses	6,464	6,134	5,836	23,946
3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items	280	542	122	281
4. Other Income	28	-	30	91
5. Profit/(Loss) from Ordinary Activities before Finance Costs	308	542	152	372
6. Finance Costs	94	72	42	272
7. Profit/(Loss) from Ordinary Activities after Finance Costs but before Exceptional Items	214	470	110	100
8. Exceptional Items	-	-	-	-
7. Profit/(Loss) from Ordinary Activities before Tax	214	470	110	100
8. Tax Expense/(Credit) (including Deferred Tax) - Earlier Year Tax	-	-	(6)	-
9. Net Profit/(Loss) for the period	214	470	116	100
10. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323
11. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				11,193
12. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):				
(a) Basic	1.29	3.04	0.70	0.60
(b) Diluted	1.29	3.04	0.70	0.60



Handwritten signature/initials



Regd. Off.: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India
 Tel: +91-22-24981650 / 66606375 ♦ Fax: +91-22-24970127
 E-mail : info@rpglifesciences.com ♦ Web: www.rpglifesciences.com
 CIN : L24232MH2007PLC169354



PART II

Select Information for the Quarter ended 30th June, 2015				
Particulars	3 months ended 30.6.2015	3 months ended 31.3.2015	3 months ended 30.6.2014	Year ended 31.3.2015
A PARTICULARS OF SHAREHOLDING				
1. Public Shareholding				
- Number of Shares	54,92,188	55,91,135	63,21,501	55,91,135
- Percentage of Shareholding	33.21	33.81	38.23	33.81
2. Promoters and Promoter Group Shareholding				
(a) Pledged/Encumbered				
- Number of Shares	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-
(b) Non-Encumbered				
- Number of Shares	110,43,917	109,44,970	102,13,740	109,44,970
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the company)	66.79	66.19	61.77	66.19

Particulars	3 months ended 30.6.2015
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	5
Disposed of during the quarter	5
Remaining unresolved during the quarter	-


Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 28th July, 2015.
2. The results for the quarter ended 30th June, 2015 have been subjected to limited review by the statutory auditors of the Company.
3. The Company is exclusively engaged in the pharmaceuticals segment.
4. Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited





CT. Renganathan
Managing Director
Mumbai, 28th July, 2015



The Board of Directors
RPG Life Sciences Limited
RPG House
463, Dr. Annie Besant Road
Worli, Mumbai – 400 030

1. We have reviewed the results of RPG Life Sciences Limited (the "Company") for the quarter ended 30th June, 2015 which are included in the accompanying 'Statement of Standalone Unaudited Results for the quarter ended 30th June, 2015 (the "Statement")', except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management but have neither been reviewed nor been audited by us. The Statement has been prepared by the Company pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges in India, which has been initialled by us for identification purposes. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. We have only traced the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in the Statement from the disclosures made by the Management and are, therefore, not expressing a review opinion thereon.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Lovelock & Lewes
Firm Registration Number: 301056E
Chartered Accountants



Sumit Seth
Partner
Membership Number 105869

Mumbai
28th July, 2015